91麻豆精品国产综合久久久,人人玩人人添人人澡超碰,五月婷婷六月激情综合,国产一级二级三级久久

Biological Activity:

BIBW2992 (Afatinib) is a highly potent and selective irreversible EGFR inhibitor, inhibiting EGFR^wt, EGFR^L858R, EGFR^L858R/T790M?and HER2 with IC₅₀?of 0.5 nM, 0.4 nM, 10 nM, 14 nM, respectively. BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, exhibits potent effects on both EGFR and HER2 phosphorylation, and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. BIBW2992 is currently undergoing Phase III clinical trials for non-small cell lung carcinoma (NSCLC) and breast cancer.

How to Use:

In vitro:? BIBW2992 was used at 1-10 μM final concentration in vitro and in cellular assays.

In vivo:?BIBW2992 was orally dosed to mice at 20 mg/kg once per day, or in combination with 2 mg/kg of Rapamycin to significantly reduce the tumor volume. Formulation: 0.5% methylcellulose/0.4% Tween-80.

?

Reference: